Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ARTEMIS trial in locally advanced rectal cancer
ISRCTN15384496Phase 2Active, not recruiting
- Sponsor
- University of Leeds
- Start
- Mar 2024
- Modality
- Small Molecules
01
Overview
Phase 2, randomised, open-label trial of palupiprant in rectal adenocarcinoma (2 arms), sponsored by University of Leeds. Primary endpoint: Clinical complete response rate at 6 months. Started Mar 2024; status: active, not recruiting.
02
Drugs
palupiprant
03
Conditions
rectal adenocarcinoma
Beyond the preview
Go deeper on ISRCTN15384496.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ISRCTN15384496.